tailieunhanh - Báo cáo y học: "Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line. | Okabe et al. Journal of Hematology Oncology 2011 4 32 http content 4 1 32 JOURNAL OF HEMATOLOGY ONCOLOGY LETTER TO THE EDITOR Open Access Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line Seiichi Okabe Tetsuzo Tauchi Yuko Tanaka and Kazuma Ohyashiki Abstract Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia CML and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study we established a nilotinib-resistant cell line K562NR and evaluated the resistance to nilotinib and efficacy of dasatinib. We found activation of Lyn plays a dominant role in survival of the nilotinib-resistant cell line. We found dasatinib induces the apoptosis of nilotinib-resistant cells and inhibits Lyn kinase activity. This novel nilotinib-resistant CML cell line may help to explore novel therapy for CML. To the editor The BCR ABL kinase inhibitor imatinib is the single effective and the standard treatment for chronic myeloid leukemia CML 1 . Resistance to imatinib is now a problem clinically. Imatinib resistance is often attributed to the emergence of clones expressing the BCR ABL mutation and several other mechanisms such as overexpression of BCR ABL and activation of Src-related kinase 2 . Nilotinib AMN107 is a new BCR ABL inhibitor and is highly selective for ABL kinase and 30-fold more potent than imatinib. Nilotinib has produced hematological and cytogenetic responses in CML patients who did not initially respond to imatinib or developed imatinib resistance 3 . Recently in Evaluating Nilotinib Efficacy and Safety in clinical Trials-newly diagnosed CML ENESTnd nilotinib has shown superior efficacy as front line treatment for patients with CML-chronic phase CP in comparison with imatinib 4 5 . Although nilotinib has shown superiority over imatinib in first-line treatment for CML-CP patients the management of CML following the .